1. Key Insights 2. IPF Market Overview at a Glance 2.1. Market Share (%) Distribution of IPF in 2017 2.2. Market Share (%) Distribution of IPF in 2028 3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF) 3.1. Introduction 3.2. Staging of IPF 3.3. Risk Factors & Disease Causes 3.4. Symptoms 3.5. Pathogenesis 3.6. Diagnosis 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. G8 Diagnosed Prevalent Population of IPF 4.3. Country Wise-Epidemiology of IPF 4.3.1. United States 4.3.1.1. Diagnosed Prevalent cases of IPF in the United States 4.3.1.2. Diagnosed Prevalent Population of IPF by severity 4.3.1.3. Gender-Specific IPF Diagnosed Prevalence 4.3.1.4. Age-Specific IPF Diagnosed Prevalence 4.3.2. Canada 4.3.2.1. Diagnosed Prevalent cases of IPF in Canada 4.3.2.2. Diagnosed Prevalent Population of IPF by severity 4.3.2.3. Gender-Specific IPF Diagnosed Prevalence 4.3.2.4. Age-Specific IPF Diagnosed Prevalence 4.3.3. EU5 4.3.3.1. Diagnosed Prevalent Population of IPF in EU5 4.3.4. France 4.3.4.1. Diagnosed Prevalent Population of IPF 4.3.4.2. Diagnosed Prevalent Population of IPF by severity 4.3.4.3. Gender-Specific IPF Diagnosed Prevalence 4.3.4.4. Age-Specific IPF Diagnosed Prevalence 4.3.5. Germany 4.3.5.1. Diagnosed Prevalent Population of IPF 4.3.5.2. Diagnosed Prevalent Population of IPF by severity 4.3.5.3. Gender-Specific IPF Diagnosed Prevalence 4.3.5.4. Age-Specific IPF Diagnosed Prevalence 4.3.6. Italy 4.3.6.1. Diagnosed Prevalent Population of IPF 4.3.6.2. Diagnosed Prevalent Population of IPF by severity 4.3.6.3. Gender-Specific IPF Diagnosed Prevalence 4.3.6.4. Age-Specific IPF Diagnosed Prevalence 4.3.7. Spain 4.3.7.1. Diagnosed Prevalent Population of IPF 4.3.7.2. Diagnosed Prevalent Population of IPF by severity 4.3.7.3. Gender-Specific IPF Diagnosed Prevalence 4.3.7.4. Age-Specific IPF Diagnosed Prevalence 4.3.8. United Kingdom 4.3.8.1. Diagnosed Prevalent Population of IPF 4.3.8.2. Diagnosed Prevalent Population of IPF by severity 4.3.8.3. Gender-Specific IPF Diagnosed Prevalence 4.3.8.4. Age-Specific IPF Diagnosed Prevalence 4.3.9. Japan 4.3.9.1. Diagnosed Prevalent Population of IPF 4.3.9.2. Diagnosed Prevalent Population of IPF by severity 4.3.9.3. Gender-Specific IPF Diagnosed Prevalence 4.3.9.4. Age-Specific IPF Diagnosed Prevalence 5. Current Treatment Practices 5.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of IPF (An Update of 2011 Clinical Practice Guideline) 6. Unmet needs 7. Marketed Products 7.1. Esbriet (Pirfenidone): InterMune Inc. 7.1.1. Product Description 7.1.2. Regulatory Milestones 7.1.3. Advantages & Disadvantages 7.1.4. Safety and Efficacy of Esbriet 7.1.5. Side effects of Esbriet 7.1.6. Product Profile 7.2. Ofev (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. 7.2.1. Product Description 7.2.2. Regulatory Milestones 7.2.3. Advantages & Disadvantages 7.2.4. Safety and Efficacy of Ofev 7.2.5. Side effects of Ofev 7.2.6. Product Profile 8. Emerging Therapies 8.1. Key Cross Competition 8.2. Thrombomodulin Alfa: Asahi Kasei Pharma Corporation 8.2.1. Drug Description 8.2.2. Product Profile 8.2.3. Clinical Development 8.2.4. Clinical Trials Information 8.2.5. Safety and Efficacy 8.3. GLPG1690: Galapagos NV 8.3.1. Drug Description 8.3.2. Product Profile 8.3.3. Regulatory Milestones 8.3.4. Other Development Activities 8.3.5. Clinical Development 8.3.6. Safety and Efficacy List To be continued in report 9. Other Promising Candidates 9.1. CC-90001: Celgene Corporation 9.1.1. Drug Description 9.1.2. Product Profile 9.1.3. Clinical Development 9.1.4. Safety and Efficacy 9.2. LT-1001: LTT Bio-Pharma 9.2.1. Drug Description 9.2.2. Product Profile 9.2.3. Regulatory Milestones 9.2.4. Other Development Activities 9.2.5. Clinical Development 9.2.6. Safety and Efficacy 9.3. BG00011: Biogen Inc 9.3.1. Drug Description 9.3.2. Product Profile 9.3.3. Regulatory Milestones 9.3.4. Other Development Activities 9.3.5. Clinical Development 9.3.6. Clinical Trials Information 9.3.7. Safety and Efficacy List To be continued in report 10. IPF: Market Analysis 10.1. Key Findings 10.2. Total Market Size of IPF in 8G 10.3. Therapy Based Market Size of IPF in 8G 10.4. Market Size of IPF by Country 10.4.1. United States Market Analysis 10.4.1.1. Market Size of IPF in the US 10.4.1.2. Therapy Based Market Size of IPF in the US 10.4.2. EU5 Market Outlook 10.4.3. Germany 10.4.3.1. Market Size of IPF in Germany 10.4.3.2. Therapy Based Market Size of IPF in Germany 10.4.4. France 10.4.4.1. Market Size of IPF in France 10.4.4.2. Therapy Based Market Size of IPF in France 10.4.5. Italy 10.4.5.1. Market Size of IPF in Italy 10.4.5.2. Therapy Based Market Size of IPF in Italy 10.4.6. United Kingdom 10.4.6.1. Market Size of IPF in the UK 10.4.6.2. Therapy Based Market Size of IPF in the UK 10.4.7. Spain 10.4.7.1. Market Size of IPF in Spain 10.4.7.2. Therapy Based Market Size of IPF in Spain 10.4.8. Japan: Market Analysis 10.4.8.1. Market Size of IPF in Japan 10.4.8.2. Therapy Based Market Size of IPF in Japan 10.4.9. Canada: market Analysis 10.4.9.1. Market Size of IPF in Japan 10.4.9.2. Therapy Based Market Size of IPF in Japan 11. Market Drivers of IPF 12. Market Barriers of IPF 13. Appendix 13.1. Report Methodology 14. DelveInsight Capabilities 15. Disclaimer 16. About DelveInsight

Table 1: Expected 1-year probability of death in patients with idiopathic pulmonary fibrosis Table 2: The GAP (Gender, Age, and Physiology) score Table 3: The GAP index and staging system Table 4: G8, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 5: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 6: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Table 7: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 8: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 9: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 10: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 11: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Table 12: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 13: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 14: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 15: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Table 16: France, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 17: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 18: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 19: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Table 20: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 21: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 22: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 23: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Table 24: The United Kingdom, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 25: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 26: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 27: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Table 28: Spain, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 29: Spain, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 30: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 31: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Table 32: Japan, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 33: Japan, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 34: Canada, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 35: Canada, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Table 36: Canada, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 37: Canada, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Table 38: Key Cross Analysis of Emerging Therapies Table 39: ART-123, Clinical Trial Description, 2019 Table 40: Pamrevlumab, Clinical Trial Description, 2019 Table 41: KD025, Clinical Trial Description, 2019 Table 42: PRM151, Clinical Trial Description, 2019 Table 43: GLPG1690, Clinical Trial Description, 2019 Table 44: CC90001, Clinical Trial Description, 2019 Table 45: LT-1001, Clinical Trial Description, 2019 Table 46: BG00011, Clinical Trial Description, 2019 Table 47: PBI4050, Clinical Trial Description, 2019 Table 49: Tipelukast, Clinical Trial Description, 2019 Table 50: TD-139, Clinical Trial Description, 2019 Table 51: VAY736, Clinical Trial Description, 2019 Table 52: TAS-115, Clinical Trial Description, 2019 Table 53: ND-L02-s0201, Clinical Trial Description, 2019 Table 54: Nalbuphine ER, Clinical Trial Description, 2019 Table 55: RVT-1601, Clinical Trial Description, 2019 Table 56: 8 Major Market Size of Idiopathic Pulmonary Fibrosis in USD Million (2017-2028) Table 57: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in G8 in USD Million (2017-2028) Table 58: Market Size of Idiopathic Pulmonary Fibrosis in the US, USD Million (2017-2028) Table 59: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US in USD Million (2017-2028) Table 60: Market Size of Idiopathic Pulmonary Fibrosis in Germany, USD Million (2017-2028) Table 61: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany in USD Million (2017-2028) Table 62: Market Size of Idiopathic Pulmonary Fibrosis in France, USD Million (2017-2028) Table 63: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France in USD Million (2017-2028) Table 64: Market Size of Idiopathic Pulmonary Fibrosis in Italy, USD Million (2017-2028) Table 65: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy in USD Million (2017-2028) Table 66: Market Size of Idiopathic Pulmonary Fibrosis in the UK, USD Million (2017-2028) Table 67: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the UK in USD Million (2017-2028) Table 68: Market Size of Idiopathic Pulmonary Fibrosis in Spain, USD Million (2017-2028) Table 69: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain in USD Million (2017-2028) Table 70: Market Size of Idiopathic Pulmonary Fibrosis in Japan, USD Million (2017-2028) Table 71:Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan in USD Million (2017-2028) Table 72: Market Size of Idiopathic Pulmonary Fibrosis in Canada, USD Million (2017-2028) Table 73:Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Canada in USD Million (2017-2028) Figure 1: Risk factors associated with IPF Figure 2: IPF associated clubbing of the fingertips Figure 3: Stages of the pathogenesis of IPF Figure 4: A schematic representing the current model for the pathogenesis of IPF Figure 5: Possible mechanisms of fibrogenesis in IPF Figure 6: Chest radiograph of a patient with idiopathic pulmonary fibrosis showing bilateral lower lobe reticular opacities Figure 7: Subpleural honeycombing in IPF diagnosed patients Figure 8: Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF). Patients with suspected IPF Figure 9: G8, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 10: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 11: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Figure 12: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 13: The United States, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 14: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 15: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 16: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Figure 17: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 18: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 19: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 20: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Figure 21: France, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 22: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 23: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 24: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Figure 25: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 26: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 27: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 28: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Figure 29: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 30: The United Kingdom, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 31: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 32: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Figure 33: Spain, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 34: Spain, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 35: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 36: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Figure 37: Japan, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 38: Japan, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 39: Canada, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 40: Canada, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2028 Figure 41: Canada, GENDER-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 42: Canada, AGE-SPECIFIC Idiopathic Pulmonary Fibrosis Prevalence, 2017-2028 Figure 43: Suggested Algorithm for IPF Treatment Figure 44: Unmet Needs of IPF Figure 45: 8 Major Market Size of Idiopathic Pulmonary Fibrosis in USD Million (2017-2028) Figure 46: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in G8 in USD Million (2017-2028) Figure 47: Market Size of Idiopathic Pulmonary Fibrosis in the US, USD Million (2017-2028) Figure 48: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US in USD Million (2017-2028) Figure 49: Market Size of Idiopathic Pulmonary Fibrosis in Germany, USD Million (2017-2028) Figure 50: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany in USD Million (2017-2028) Figure 51: Market Size of Idiopathic Pulmonary Fibrosis in France, USD Million (2017-2028) Figure 52: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France in USD Million (2017-2028) Figure 53: Market Size of Idiopathic Pulmonary Fibrosis in Italy, USD Million (2017-2028) Figure 54: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy in USD Million (2017-2028) Figure 55: Market Size of Idiopathic Pulmonary Fibrosis in the UK, USD Million (2017-2028) Figure 56: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in The UK in USD Million (2017-2028) Figure 57: Market Size of Idiopathic Pulmonary Fibrosis in Spain, USD Million (2017-2028) Figure 58: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain in USD Million (2017-2028) Figure 59: Market Size of Idiopathic Pulmonary Fibrosis in Japan, USD Million (2017-2028) Figure 60: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan in USD Million (2017-2028) Figure 61: Market Size of Idiopathic Pulmonary Fibrosis in Canada, USD Million (2017-2028) Figure 62: Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Canada in USD Million (2017-2028) Figure 63: Market Drivers of IPF Figure 64: Market Barriers of IPF

1.InterMune Inc. 2.Boehringer Ingelheim Pharma GmbH & Co. 3.Asahi Kasei Pharma Corporation 4.Galapagos NV 5.Celgene Corporation 6.LTT Bio-Pharma 7.Biogen Inc and others.